Observational pilot study of patients with carpal tunnel syndrome treated with Nucleo CMP Forte™

Pain Manag. 2019 Mar 1;9(2):123-129. doi: 10.2217/pmt-2018-0050. Epub 2018 Nov 19.

Abstract

Aim: Carpal tunnel syndrome (CTS) is a very common entrapment neuropathy characterized by pain and paresthesia in the territory of the median nerve. Although this syndrome has a considerable impact on the patient's quality of life, its medical treatment is far from optimal.

Material & methods: We performed an observational study to evaluate Nucleo CMP ForteTM in patients with electromyography-confirmed, mild-moderate CTS. Pain was assessed using a visual analog scale, electromyogram and the SF-36.

Results: Pain decreased significantly after 6 months. Quality of life improved significantly in the pain dimensions. No significant differences were observed in electromyographic findings. No adverse events were reported.

Conclusions: Nucleotides could prove useful for the nonsurgical treatment of CTS. Further studies are necessary to confirm this.

Keywords: carpal tunnel syndrome; electromyography; nucleotides; pain.

Publication types

  • Observational Study

MeSH terms

  • Analgesics / therapeutic use*
  • Carpal Tunnel Syndrome / complications*
  • Carpal Tunnel Syndrome / physiopathology
  • Cytidine Monophosphate / therapeutic use*
  • Electromyography
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pain / drug therapy*
  • Pain / etiology
  • Pain Measurement
  • Pilot Projects
  • Quality of Life
  • Treatment Outcome
  • Uridine Monophosphate / therapeutic use*

Substances

  • Analgesics
  • Uridine Monophosphate
  • Cytidine Monophosphate